fibrinolytic TAFIa carboxypeptidase inhibitor

Ph. II candidate for pulm. embolism; discont.

from literature pharmacophore and SBDD

J. Med. Chem., Mar. 25, 2021

Servier, Croissy-sur-Seine, FR

The Servier thrombin activatable fibrinolysis inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot degrading) agent which entered Ph. II in the EU for pulmonary embolism, but development appears to have been…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.